34th week of 2011 patent applcation highlights part 47 |
Patent application number | Title | Published |
20110207630 | METHOD FOR TESTING AND QUALITY CONTROLLING OF NUCLEIC ACIDS ON A SUPPORT - The present invention relates to a method for testing nucleic acids on a support, comprising the immobilization of one or more nucleic acids via crosslinking, wherein each of the immobilized nucleic acids includes a stretch of nucleotides of only one basetype, the provision of labeled oligonucleotides complementary to said stretch of nucleotides, and the determination of a value indicative for the condition of said nucleic acids. The present invention further relates to a kit for testing nucleic acids on a support comprising an array of nucleic acids immobilized on a solid support, wherein each of the immobilized nucleic acids includes a stretch of nucleotides of only one basetype and a labeled oligonucleotide complementary to said stretch of nucleotides. The invention additionally concerns the use of a labeled oligonucleotide complementary to a stretch of nucleotides of only one basetype for testing the condition of nucleic acids immobilized on a solid support. | 2011-08-25 |
20110207631 | METHOD FOR PRODUCTION OF cDNA LIBRARY HAVING REDUCED CONTENT OF cDNA CLONE DERIVED FROM HIGHLY EXPRESSED GENE - A method for efficiently constructing a cDNA library having a reduced content of cDNA clones derived from a highly expressed gene is provided. According to the method for constructing a cDNA library using a double-stranded DNA primer having oligo dT and mRNA as a template, the proportion of cDNA clones derived from a highly expressed gene in a cDNA library was decreased through coexistence with a probe having a property of binding to the mRNA of the highly expressed target gene so as to inhibit a cDNA extension reaction resulting from reverse transcriptase. | 2011-08-25 |
20110207632 | TEMPERATURE CONTROL DEVICE WITH A FLEXIBLE TEMPERATURE CONTROL SURFACE - A device for controlling temperature in a reaction chamber is disclosed. The device comprises: a bladder assembly comprising a housing dimensioned to hold a reaction chamber disposed within an interior volume of the housing; and a first temperature-control bladder disposed within the housing, the first temperature-control bladder is configured to receive a temperature-control fluid and comprises a flexible, heat conductive surface that comes in contact with at least a portion of an exterior surface of the reaction chamber after receiving the temperature-control fluid. Also disclosed are a bladder thermal cycler, a temperature-control bladder assembly and methods for producing a thermal cycle in a reaction chamber. | 2011-08-25 |
20110207633 | DEEP EUTECTIC SOLVENTS AND APPLICATIONS - A method of solubilizing/removing cellulose or chemically-modified cellulosic polymers utilized in subterranean drilling operations such as fracturing. The method involves introducing a deep eutectic solvent (DES) into a subterranean region. Deep eutectic solvents useful as cellulose solvents include quaternary ammonium compounds, including choline chloride and chlorcholine chloride, reacted with a compound selected from amides, amines, carboxylic acids alcohols, and metal halides. The DES material can be pumped downhole after fracturing operations to remove cellulosic material used, for example, to thicken fracturing fluid which is left behind in the created fractures, on the face of the formation, along the wellbore, or elsewhere within the subterranean region. The DES can be used alone or in a sequential treatment protocol, whereby the DES is introduced into the subterranean region, followed by post-treatment introduction of water, caustic, acid or anhydride into the subterranean as a flush. | 2011-08-25 |
20110207634 | PREPARING ETHER CARBOXYLATES - The present invention relates to a process for preparing ether carboxylates. | 2011-08-25 |
20110207635 | Lubricating Composition Containing Metal Carboxylate - The invention relates to a lubricating composition comprising (a) at least 0.05 wt % of a non-aromatic metal carboxylate, wherein the metal carboxylate is derived from a branched carboxylic acid, and (b) an oil of lubricating viscosity. The invention further provides for the use of the lubricating composition for lubricating a limited slip differential. | 2011-08-25 |
20110207636 | LOW VISCOSITY FUNCTIONAL FLUIDS - Low viscosity functional fluids are described which comprise glycols and an additive package that includes a fatty acid and a phosphate ester, such as a phosphate ester of an alkyl, alkenyl, or aryl alcohol. The fluids are particularly well-suit for use as DOT 3 or DOT 4 brake fluids and provide robust lubricity and corrosion inhibition. | 2011-08-25 |
20110207637 | Vicinally Disubstituted Internal Olefins as Constituents of Olefin Copolymers for Lubricating Oil Rheology Modifiers - This invention relates to an ethylene copolymer for lubricating oil, comprising: ethylene; at least one alpha-olefin having 3 or more carbon atoms; and at least one vicinally substituted olefin having 2 to 40 carbon atoms, wherein: the copolymer has a weight-average molecular weight (Mw) of about 50,000 to about 500,000; and an intensity ratio of S | 2011-08-25 |
20110207638 | COMPOSITION OF BIODEGRADABLE GEAR OIL - A composition of biodegradable gear oil that mainly contains modified nontauedible vegetable oils. Mono-esters are hydrogenated, epoxidized or aryl alkylated or mixture thereof, and C7 to C12 primary alcohol. In addition to chemically modified non-edible vegetable oils, the composition also contains an additive pack, which comprises at least one: antioxidant, an extreme pressure additive, an anti foaming agent, a pour point depressant, a corrosion inhibitor and a detergent-dispersant additive. The product of this invention has utility as industrial and automotive gear oil GL 4 grade. The compositions are significantly biodegradable, eco-friendly, reduce use of petroleum, have lower cost than synthetic oil, are miscible in mineral & synthetic fluids and safe to use due to higher flash point. | 2011-08-25 |
20110207639 | METHOD FOR IMPROVING THE FUEL EFFICIENCY OF ENGINE OIL COMPOSITIONS FOR LARGE LOW AND MEDIUM SPEED ENGINES BY REDUCING THE TRACTION COEFFICIENT - The present invention is directed to a method for improving the fuel efficiency of large low and medium speed engine oil compositions by reducing the traction coefficient of the oil by formulating the oil using a blend consisting of one or more Group I base oils having a kinematic viscosity at 100° C. of from 2 to less than 12 mm | 2011-08-25 |
20110207640 | POLY (HYDROXYCARBOXYLIC ACID) AMIDE SALT DERIVATIVE AND LUBRICATING COMPOSITION CONTAINING IT - The present invention provides a poly(hydroxycarboxylic acid) amide salt derivative having formula (III): [Y—CO[O-A-CO] | 2011-08-25 |
20110207641 | PROCESS FOR PREPARING FINE POWDER POLYUREA AND GREASES THEREFROM - Polyurea compounds are prepared by reacting amines and polyisoyanates in the presence of a liquid diluent in a high-pressure impingement mixing device under conditions sufficient to produce polyurea compounds having the consistency of a powder and in which diluent is dispersed. | 2011-08-25 |
20110207642 | Lubricating Oil Composition - A lubricating oil composition comprising: (A) an oil of lubricating viscosity in a major amount, comprising a Group III base stock; (B) as an additive component in a minor amount, a viscosity index improver comprising a linear or star-shaped polymer which is derivable, at least in part, from the polymerisation of one or more conjugated diene monomers; and, wherein the lubricating oil composition is contaminated with at least 0.3 mass %, based on the total mass of the lubricating oil composition, of a biofuel or a decomposition product thereof and mixtures thereof. | 2011-08-25 |
20110207643 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT - The present invention relates to a product of reaction between a primary and/or secondary amine and one or more active ingredients. By the present invention, there is provided a release of the active component over a longer period of time than by the use of the active itself. | 2011-08-25 |
20110207644 | SALINE NOSE WIPE AND METHODS OF MANUFACTURE AND USE - The present invention generally relates to a wet wipe or sheet that is suitable for contacting the skin and removing mucus from the skin. More specifically, the present invention relates to a wet wipe having an aqueous saline component suitable for dissolving and removing mucus in combination with the fabric matrix of the wet wipe. Typically, the fabric matrix of the wet wipe has a capacity of about 125 grams of solution per square meter, and it is impregnated with the aqueous saline solution to a level at or below approximately 80% of the absorbent capacity of the matrix. | 2011-08-25 |
20110207645 | Non-aqueous, non-corrosive microelectronic cleaning compositions containing polymeric corrosion inhibitors - Photoresist strippers and cleaning compositions of this invention are provided by non-aqueous cleaning compositions that are essentially non-corrosive toward copper as well as aluminum and that comprise at least one polar organic solvent, at least one hydroxylated organic amine, and at least one corrosion inhibitor polymer having multiple hydroxyl- or amino-functional groups pendant from the polymer backbone. | 2011-08-25 |
20110207646 | Detergent Composition - A phosphate-free automatic dishwashing detergent composition comprising: | 2011-08-25 |
20110207647 | COMPOSITION - A dishwasher detergent composition, preferably pH neutral, and comprising a strong biodegradable builder and optionally a bleach, and optionally a sulfonated polymer. | 2011-08-25 |
20110207648 | Use Of N,N-Bis(2-Hydroxyethyl)Cocoamine Oxide For The Cleaning Of Hard Surfaces - The use of compositions comprising N,N-bis(2-hydroxyethyl)cocoamine oxide for the cleaning of hard surfaces consisting of materials selected from ceramic, metal, wood, glass and plastic from lime-containing soil is described. | 2011-08-25 |
20110207649 | STABLE ANTIMICROBIAL COMPOSITIONS INCLUDING SPORE, BACTERIA, FUNGI AND/OR ENZYME - The present invention relates to a stable antimicrobial and cleaning compositions including an amine antimicrobial agent; a borate salt; and spores (bacterial or fungal), vegetative bacteria, fungi, or enzyme, and to methods of using the composition. The composition can also include a polyol. | 2011-08-25 |
20110207650 | ANTI-FOAMING COMPOSITIONS - Effective defoaming compositions contains specific polyoxyalkylene-substituted organopolysiloxanes and at least one additive which is a particulate filler or an organopolysiloxane resin. | 2011-08-25 |
20110207651 | PREPARING ETHER CARBOXYLATES - The present invention relates to a process for preparing ether carboxylates. | 2011-08-25 |
20110207652 | FAST DRYING AND FAST DRAINING RINSE AID - The present invention is directed to rinse aid compositions and methods for making and using the rinse aid compositions. The compositions of the invention include a sheeting agent, a defoaming agent, and an association disruption agent. The rinse aid compositions of the present invention result in a faster draining/drying time on most substrates compared to conventional rinse aids. The rinse aid compositions of the present invention are especially suitable for use on plastic substrates. | 2011-08-25 |
20110207653 | Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent - The present invention relates to polymeric microparticles comprising a therapeutic polypeptide along with a redox reagent. Also disclosed are methods of using the microparticles, including methods of using the microparticles for delivery of the therapeutic polypeptide to a subject in need thereof. | 2011-08-25 |
20110207654 | PEPTIDE ANALOGUES - The present invention relates to compounds of Formula (I) | 2011-08-25 |
20110207655 | CYCLIC DEPSIPEPTIDE COMPOUND AND USE THEREOF - [Problem]A compound useful for the prevention and/or treatment of chronic obstructive pulmonary disease (COPD) or asthma, and a pharmaceutical composition containing the compound as an active ingredient are provided. | 2011-08-25 |
20110207656 | MUC1, CASPASE-8, and DED-CONTAINING PROTEINS - The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of, e.g., a variety of pathological disorders characterized by elevated or decreased levels of apoptosis. Moreover, the compositions and methods are also useful to identify, design, and generate compounds that modulate the interactions. The compounds and/or pharmaceutical compositions containing the compounds can be used in the treatment of disease. | 2011-08-25 |
20110207657 | Selectively Targeted Antimicrobial Peptides and the Use Thereof - The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., | 2011-08-25 |
20110207658 | High Purity Lipopeptides - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of | 2011-08-25 |
20110207659 | OLIGOSACCHARIDE COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF INFECTION - Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described. | 2011-08-25 |
20110207660 | PHARMACEUTICAL FORMULATIONS OF AN HCV PROTEASE INHIBITOR IN A SOLID MOLECULAR DISPERSION - The present invention provides pharmaceutical formulations of an HCV protease inhibitor in a solid dispersion with an excipient which provided advantageous pharmacokinetic properties for inhibiting or treating HCV infection. In preferred embodiments, the excipient is at least one polymer. The present invention also provides processes for manufacturing such formulations as well as uses of said composition for the manufacture of a medicament for treating or ameliorating one or more symptoms of HCV or disorders associated with HCV in a subject in need thereof using said formulations. | 2011-08-25 |
20110207661 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition. | 2011-08-25 |
20110207662 | Composition for Long-Acting Peptide Analogs - The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm) | 2011-08-25 |
20110207663 | FIBROBLAST GROWTH FACTOR (FGF) ANALOGS AND USES THEREOF - The invention relates to novel peptide comprising FGF-P and methods of use thereof. | 2011-08-25 |
20110207664 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins - The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors. | 2011-08-25 |
20110207665 | METHOD OF REGULATING PROLIFERATION AND DIFFERENTIATION OF KERATINOCYES - Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide to a subject. | 2011-08-25 |
20110207666 | METHOD OF PROMOTING BONE GROWTH WITH HYALURONIC ACID AND GROWTH FACTORS - A bone growth-promoting composition is provided comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to persist at an intra-articular site of desired bone growth for a period of time sufficient to promote the bone growth. Preferably hyaluronic acid is used in a composition range of 0.1-4% by weight and preferred growth factor is bFGF, present in a concentration range of about 10 | 2011-08-25 |
20110207667 | EFFICIENT EXPRESSION OF TRUNCATED HUMAN RNASET2 IN E. COLI - An isolated, recombinant truncated human RNASET2 having anti-angiogenic properties, methods for efficient expression thereof in bacteria and therapeutic uses thereof. | 2011-08-25 |
20110207668 | BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 2011-08-25 |
20110207669 | RECOMBINANT PROTEINS HAVING HAEMOSTATIC ACTIVITY AND CAPABLE OF INDUCING PLATELET AGGREGATION - Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof. | 2011-08-25 |
20110207670 | COMPOSITIONS AND METHODS OF USE FOR SOLUBLE THROMBOMODULIN VARIANTS - The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind thrombin will prevent or reduce acute kidney injury and subsequent morbidity and mortality. | 2011-08-25 |
20110207671 | METHOD FOR PRODUCING DOUBLE-CROSSLINKED COLLAGEN - The present invention relates to double-crosslinked collagen materials, methods for preparing double-crosslinked collagen materials, and methods of using double-crosslinked | 2011-08-25 |
20110207672 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID - This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. | 2011-08-25 |
20110207673 | METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION - Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers. | 2011-08-25 |
20110207674 | ANTITUMORAL COMPOUNDS -
Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof
| 2011-08-25 |
20110207675 | GENE FUSION TARGETED THERAPY - The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer. | 2011-08-25 |
20110207676 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 2011-08-25 |
20110207677 | Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Chronic or Non-Chronic Inflammatory Digestive Diseases - The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc. | 2011-08-25 |
20110207678 | CD44 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, ANTIBODIES DIRECTED THEREAGAINST AND METHOD OF USING SAME FOR DIAGNOSING AND TREATING INFLAMMATORY DISEASES - An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6. | 2011-08-25 |
20110207679 | METHODS OF TREATMENT USING IL-16 ANTAGONIST PEPTIDES - The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases. | 2011-08-25 |
20110207680 | Administration of Glufosfamide For The Treatment of Cancer - Administration of Glufosfamide alone and in combination with another anticancer agent is useful for the treatment of gall bladder cancer. | 2011-08-25 |
20110207681 | USE OF GLUCOSYLGLYCEROL - The invention relates to the use of glucosylglycerol or glucosylglycerol esters with a view to increasing the expression of cell protective enzymes for the protection and stabilization of human skin and/or mucous membranes. It has been demonstrated that glucosylglycerol plays an effective role in the stimulation and activation of cell protective enzymes such as superoxide dismutase. It is thus possible in this manner to protect human skin cells effectively against damaging external influences. | 2011-08-25 |
20110207682 | PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF PEPTIC ULCER DISEASES - The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant | 2011-08-25 |
20110207683 | NATURAL COLORANT AND METHODS THEREOF - To provide a material composed mainly of a material derived from dragon fruit having to provide a supplement, a drug, a cosmetic or a food produced by using the material. The invention provides a material derived from dragon fruit, especially, a powder of dragon fruit, and a supplement, a drug, a cosmetic or a food containing the above material as a component. | 2011-08-25 |
20110207684 | NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ISONIAZID - The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds. Said compound was selected from the following groups of compounds: Nordihydroguaiaretic acid, Trans-Cinnamaldehyde, Daidzein, Isovitexin, Kaempferol, disulfuram, β-Myrcene, Quercetin, (−)-Epigallocatechin-3-gallate, (+)-Limonene, Myricetin, Quercitrin, Luteolin-7-Glucoside, Morin, Neohesperidin, Hesperidin, Capillarisin, (−)-Epigallocatechin, Luteolin, Hyperoside, Ethyl Myristate, Tamarixetin, Phloretin, Baicalein, Rutin, Baicalin, Apigenin, Naringenin, Hesperetin, (+)-Epicatechin, (−)-Epicatechin-3-gallat, Isoliquritigenin, Silybin, Vitexin, Genistein, Isorhamnetin, gallic acid, Diosmin, 6-Gingerol, (+)-Taxifolin, Wongonin, Protocatechuic acid, (+)-Catechin, β-naphthoflavone, Embelin, Trans-Cinnamic acid, (−)-Epicatechin, Phloridzin, Puerarin, Umbelliferone, Brij 58, Brij 76, Brij 35, Tween 20, Tween 80, Tween 40, PEG 2000, PEG 400, Pluornic F68, and PEG 4000. The novel, low side-effect compound complex which contains pharmaceutically effective doses of isoniazid (INH), disulfuram (DSF) and/or a third compound, bis-nitrophenyl phosphate (BNPP) can reduce isoniazid (INH)-induced side effects, e.g. hepatotoxicity, etc. | 2011-08-25 |
20110207685 | Oral Formulations of Chemotherapeutic Agents - The present invention is directed to new oral formulations of chemotherapeutic agents, their process of preparation as well as their therapeutic uses. More specifically, said invention is related to nanoparticles comprising at least one chemotherapeutic agents as an active ingredient, at least one polymer and at least one cyclic oligosaccharide capable of complexing said camptothecin derivative, said nanoparticles being for therapeutic oral administration. | 2011-08-25 |
20110207686 | POLYSACCHARIDE-AND POLYPEPTIDE-BASED BLOCK COPOLYMERS, VESICLES CONSTITUTED BY THESE COPOLYMERS AND USE THEREOF - The invention relates to a new type of polysaccharide-block-polypeptide diblock copolymer which is bioresorbable or biodegradable and biocompatible, to a method for preparing same, to the micellar vesicles constituted of this copolymer, and to the use thereof for encapsulation, transport, vectorization, and targeting of molecules of interest. | 2011-08-25 |
20110207687 | FULVIC ACID AND ANTIBIOTIC COMBINATION - This invention relates to a fulvic acid and antibiotic combination for use in the treatment of various diseases and conditions. The invention further relates to the use of the combination for the treatment of various diseases and conditions, including bacterial infection. In particular, the bacteria are antibiotic resistant bacteria. | 2011-08-25 |
20110207688 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R | 2011-08-25 |
20110207689 | THE TREATMENT OF HEARING LOSS - The invention provides a method of treating noise-induced hearing loss, the method including the step of administering an A | 2011-08-25 |
20110207690 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: | 2011-08-25 |
20110207691 | COBALAMIN COMPOSITIONS FOR THE TREATMENT OF CANCER - Compositions are provided that contain a combination of a nitric oxide-cobalamin complex along with at least one cobalamin drug conjugate, together with methods for their use in the treatment of neoplastic disease. | 2011-08-25 |
20110207692 | COMBINATIONS OF SAPACITABINE OR CNDAC WITH DNA METHYLTRANSFERASE INHIBITORS SUCH AS DECITABINE AND PROCAINE - A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject. | 2011-08-25 |
20110207693 | Oral B12 Therapy - Methods of normalizing vitamin B | 2011-08-25 |
20110207694 | MAMMALIAN HYPOTHALAMIC NUTRIENT MODULATION OF GLUCOSE METABOLISM - Provided are methods of reducing glucose production in a mammal, methods of reducing food intake in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, methods of reducing peripheral blood glucose levels in a mammal, methods of decreasing serum triglyceride levels in a mammal, and methods of decreasing very low density lipoprotein (VLDL) levels in a mammal. | 2011-08-25 |
20110207695 | AGENT FOR APPLYING TO MUCOSA AND METHOD FOR THE PRODUCTION THEREOF - An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient. | 2011-08-25 |
20110207696 | Compositions for treating rosacea - The present invention is directed to compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, and a short-medium chain dicarboxylic acid amide, or a physiologically acceptable salt thereof, forming a film after application onto the skin, useful for protecting skin of the face and of other affected areas in couperose, rosacea and telangiectasia of the legs. | 2011-08-25 |
20110207697 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS - The present invention features therapeutic and prophylactic compositions comprising xanthohumol and/or xanthohumol/cyclodextrin complexes and methods of using such compositions for treating a skin condition, disease, or disorder. | 2011-08-25 |
20110207698 | HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE - The present application relates to novel heteroaryl-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders. | 2011-08-25 |
20110207699 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2011-08-25 |
20110207700 | TRICYCLIC COMPOUND AND USE THEREOF - The present invention relates to the compound represented by formula (I): | 2011-08-25 |
20110207701 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS - This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 2011-08-25 |
20110207702 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS - This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 2011-08-25 |
20110207703 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF - Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. | 2011-08-25 |
20110207704 | Novel Oxadiazole Compounds - Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed. | 2011-08-25 |
20110207705 | OVIEDOMYCIN DERIVATIVES, METHOD FOR OBTAINING SAME AND USE THEREOF - Oviedomycin derivatives, method for obtaining same and use thereof. This invention relates to oviedomycin derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and to produce the oviedomycin derivatives. The invention further relates to bacterial strains that can be used to produce oviedomycin derivatives. Finally, said oviedomycin derivatives are applicable in the field of the human health, specifically to produce drugs for the treatment of tumour diseases. | 2011-08-25 |
20110207706 | Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds - Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described. | 2011-08-25 |
20110207707 | Compounds That Act To Modulate Insect Growth And Methods And Systems For Identifying Such Compounds - Disclosed are methods and systems for screening for compounds that act to modulate insect growth. Bioassays including cell culture and/or transgenic insects engineered with various components of the ecdysoid receptor (EcR) and/or the farsenoid-X receptor (RXR) systems to identify compounds that act as insecticides and/or hormone receptor activators are described. Also described are compounds, and compositions, identified as being putative insecticides based upon their ability to activate EcR and/or FXR mediated transcription. | 2011-08-25 |
20110207708 | Androgen Treatment in Females - The present invention is directed to a method of using dehydroepiandrosterone to treat a human female with diminished ovarian reserve. The method includes administering about 25 milligrams three times a day of dehydroepiandrosterone per day to the female for at least four weeks to reduce human embryo aneuploidy. The present invention further is directed to a method of treating a human female with diminished ovarian reserve to improve the female's diminished ovarian reserve. | 2011-08-25 |
20110207709 | MODULATORS OF SEROTONIN RECEPTOR - Certain biphenyl compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 2011-08-25 |
20110207710 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES - Administration of sPLA | 2011-08-25 |
20110207711 | Therapeutic Compounds - The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. | 2011-08-25 |
20110207712 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use - The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases. | 2011-08-25 |
20110207713 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE - Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2011-08-25 |
20110207714 | SEROTONIN RECEPTOR MODULATORS - The biphenyic compounds of formula (I) are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 2011-08-25 |
20110207715 | Disubstituted Azepan Orexin Receptor Antagonists - The present invention is directed to disubstituted azepan and oxazepan amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2011-08-25 |
20110207716 | INHIBITORS OF POLO-LIKE KINASE - The present invention provides compounds having a structure according to Formula (I): | 2011-08-25 |
20110207717 | 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS - Certain 2-aminopyrimidine compounds are serotonin receptor modulators useful in the treatment of diseases mediated by serotonin receptors. | 2011-08-25 |
20110207718 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS - Methods of treating psychiatric disorders are provided which include administration of one or more anti-epileptic agents and, optionally, one or more a psychostimulants. Also provided are pharmaceutical compositions comprising, in combination, one or more anti-epileptic agents and one or more psychostimulants. Psychiatric disorders include those associated with impaired cognitive processing, degenerative disorders such as Mild Cognitive Impairment, Parkinson's disease, dementia, non-compliance with therapeutic regimes and eating disorders, although without limitation thereto. | 2011-08-25 |
20110207719 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof - A series of novel anthra[1,2-d]imidazole-6,11-dione derivatives, and the preparation method and application of said derivatives, wherein said application includes a pharmaceutical composition containing said derivatives for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell, treating cancer and the like. | 2011-08-25 |
20110207720 | QUINOLIN-4-ONE AND 4-OXODIHYRDOCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) - The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment. | 2011-08-25 |
20110207721 | PURINE DERIVATIVES AS KINASE INHIBITORS - The present invention provides kinase inhibitors of Formula I. | 2011-08-25 |
20110207722 | TREATMENT OF ANXIETY DISORDERS - This invention relates to the treatment of anxiety disorders. The invention furthermore relates to novel pharmaceutical compositions comprising a therapeutically effective amount of the compound exo-7-(8-H-8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one, or a therapeutically effective amount of the compound exo- 7-(8-H-8- aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one and a benzodiazepine drug. | 2011-08-25 |
20110207723 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE - A compound represented by the general formula (I): | 2011-08-25 |
20110207724 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE WHICH COMBINE NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS WITH ANIT-HYPERTENSIVE COMPOUNDS - An oral dosage form of a non-steroidal anti-inflammatory drug (NSAID) is rendered safer for extended or chronic use for anti-inflammatory, analgesic or antipyretic therapy by combining it with an antihypertensive drug. The antihypertensive drug acts prophylactically to inhibit or reduce NSAID-induced hypertension and by so doing the adverse cardiovascular side effects of NSAIDs, such as high blood pressure, heart attack, stroke, opththamologic complications, and death, when NSAIDs are used repetitively over an extended period of time for reducing inflammation or in pain management. | 2011-08-25 |
20110207725 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X | 2011-08-25 |
20110207726 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S - The present invention is directed to novel protease inhibitors that are specific for cathepsin L, cathepsin B, and cathepsin S. Accordingly, the present invention encompasses compositions and methods for treating and preventing diseases and disorders associated with cathepsin L, cathepsin B, or cathepsin S function or activity. | 2011-08-25 |
20110207727 | Thio-subsituted Anthra [1, 2-d] imidazole- 6, 11-dione Dervatives, Preparation Method and application thereof - A series of novel thio-substituted anthra[1,2-d]imidazole-6,11-dione dervatives, and the preparation method and application of said derivatives, said application having a pharmaceutical composition containing said derivatives with therapeutically effective amount for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell, treating cancer and the like. | 2011-08-25 |
20110207728 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS - The present invention relates to compounds of formula (I) | 2011-08-25 |
20110207729 | BICYCLIC ACYLGUANIDINE DERIVATIVE - An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT | 2011-08-25 |